Iovance Biotherapeutics (IOVA) Short-term Investments (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Short-term Investments of $116.9 million for Q1 2026, down 37.82% year-over-year from $188.0 million in Q1 2025, and down 12.67% quarter-over-quarter from $133.9 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Short-term Investments (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Short-term Investments for 14 consecutive years, with $116.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments fell 37.82% year-over-year to $116.9 million; the TTM figure through Mar 2026 stood at $116.9 million (down 37.82% YoY), while the FY2025 annual figure was $133.9 million, down 35.65% from the prior year.
- Short-term Investments fell to $116.9 million in Q1 2026 per IOVA's latest filing, from $133.9 million in the prior quarter.
- Across five years, Short-term Investments topped out at $389.8 million in Q1 2022 and bottomed at $20.9 million in Q2 2023.
- Historically, Short-term Investments has averaged $182.1 million across 5 years, with a median of $168.7 million in 2025.
- Annual changes were most pronounced in 2023 — Short-term Investments plunged 93.39% — and 2024, when it soared 168.1%.
- Iovance Biotherapeutics' Short-term Investments stood at $240.1 million in 2022, then plunged by 31.29% to $165.0 million in 2023, then rose by 26.13% to $208.1 million in 2024, then slumped by 35.65% to $133.9 million in 2025, then retreated by 12.67% to $116.9 million in 2026.
- Business Quant data shows IOVA's Short-term Investments at $116.9 million in Q1 2026, $133.9 million in Q4 2025, and $142.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 186.91 Mn |
| Mar 31, 2026 | 116.94 Mn |
| Dec 31, 2025 | 133.90 Mn |
| Sep 30, 2025 | 142.70 Mn |
| Jun 30, 2025 | 168.70 Mn |
| Mar 31, 2025 | 188.05 Mn |
| Dec 31, 2024 | 208.09 Mn |
| Mar 31, 2024 | 222.01 Mn |
| Dec 31, 2023 | 164.98 Mn |
| Sep 30, 2023 | 93.65 Mn |
| Jun 30, 2023 | 20.90 Mn |
| Mar 31, 2023 | 82.81 Mn |
| Dec 31, 2022 | 240.11 Mn |
| Sep 30, 2022 | 241.81 Mn |
| Jun 30, 2022 | 316.40 Mn |
| Mar 31, 2022 | 389.80 Mn |
| Dec 31, 2021 | 426.18 Mn |
| Sep 30, 2021 | 517.90 Mn |
| Jun 30, 2021 | 573.60 Mn |
| Mar 31, 2021 | 472.20 Mn |